Literature DB >> 20937841

Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.

Kyle E Landgraf1, Lydia Santell, Karen L Billeci, Clifford Quan, Judy C Young, Henry R Maun, Daniel Kirchhofer, Robert A Lazarus.   

Abstract

Hepatocyte growth factor (HGF) binds to its target receptor tyrosine kinase, Met, as a single-chain form (pro-HGF) or as a cleaved two-chain disulfide-linked α/β-heterodimer. However, only two-chain HGF stimulates Met signaling. Proteolytic cleavage of the Arg(494)-Val(495) peptide bond in the zymogen-like pro-HGF results in allosteric activation of the serine protease-like β-chain (HGF β), which binds Met to initiate signaling. We use insights from the canonical trypsin-like serine protease activation mechanism to show that isolated peptides corresponding to the first 7-10 residues of the cleaved N terminus of the β-chain stimulate Met phosphorylation by pro-HGF to levels that are ∼25% of those stimulated by two-chain HGF. Biolayer interferometry data demonstrate that peptide VVNGIPTR (peptide V8) allosterically enhances pro-HGF β binding to Met, resulting in a K(D)(app) of 1.6 μm, only 8-fold weaker than the Met/HGF β-chain affinity. Most notably, in vitro cell stimulation with peptide V8 in the presence of pro-HGF leads to Akt phosphorylation, enhances cell survival, and facilitates cell migration between 75 and 100% of that found with two-chain HGF, thus revealing a novel approach for activation of Met signaling that bypasses proteolytic processing of pro-HGF. Peptide V8 is unable to enhance Met binding or signaling with HGF proteins having a mutated activation pocket (D672N). Furthermore, Gly substitution of the N-terminal Val residue in peptide V8 results in loss of all activity. Overall, these findings identify the activation pocket of the serine protease-like β-chain as a "hot spot" for allosteric regulation of pro-HGF and have broad implications for developing selective allosteric activators of serine proteases and pseudoproteases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937841      PMCID: PMC3001016          DOI: 10.1074/jbc.M110.179721

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.

Authors:  Ermanno Gherardi; Mark E Youles; Ricardo N Miguel; Tom L Blundell; Luisa Iamele; Julian Gough; Abhishek Bandyopadhyay; Guido Hartmann; P Jonathan G Butler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

2.  Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation.

Authors:  Rainer Friedrich; Peter Panizzi; Pablo Fuentes-Prior; Klaus Richter; Ingrid Verhamme; Patricia J Anderson; Shun-Ichiro Kawabata; Robert Huber; Wolfram Bode; Paul E Bock
Journal:  Nature       Date:  2003-10-02       Impact factor: 49.962

Review 3.  The Met pathway: master switch and drug target in cancer progression.

Authors:  Massimiliano Mazzone; Paolo M Comoglio
Journal:  FASEB J       Date:  2006-08       Impact factor: 5.191

4.  Turning enzymes ON with small molecules.

Authors:  Julie A Zorn; James A Wells
Journal:  Nat Chem Biol       Date:  2010-03       Impact factor: 15.040

5.  Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

Authors:  Daniel Kirchhofer; Mark Peek; Michael T Lipari; Karen Billeci; Bin Fan; Paul Moran
Journal:  FEBS Lett       Date:  2005-03-28       Impact factor: 4.124

6.  Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.

Authors:  Mark Peek; Paul Moran; Nerissa Mendoza; Dineli Wickramasinghe; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2002-10-07       Impact factor: 5.157

7.  Zymogen activation in the streptokinase-plasminogen complex. Ile1 is required for the formation of a functional active site.

Authors:  S Wang; G L Reed; L Hedstrom
Journal:  Eur J Biochem       Date:  2000-07

Review 8.  Cofactor-induced and mutational activity enhancement of coagulation factor VIIa.

Authors:  O H Olsen; E Persson
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

9.  Diverse and potent activities of HGF/SF in skin wound repair.

Authors:  Damon Bevan; Ermanno Gherardi; Tai-Ping Fan; Dylan Edwards; Richard Warn
Journal:  J Pathol       Date:  2004-07       Impact factor: 7.996

10.  Hepatocyte growth factor accelerates the wound repair of cultured gastric mucosal cells.

Authors:  S Watanabe; M Hirose; X E Wang; K Maehiro; T Murai; O Kobayashi; A Nagahara; N Sato
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

View more
  9 in total

Review 1.  Conformational selection in trypsin-like proteases.

Authors:  Nicola Pozzi; Austin D Vogt; David W Gohara; Enrico Di Cera
Journal:  Curr Opin Struct Biol       Date:  2012-06-03       Impact factor: 6.809

2.  An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.

Authors:  Kyle E Landgraf; Micah Steffek; Clifford Quan; Jeffrey Tom; Christine Yu; Lydia Santell; Henry R Maun; Charles Eigenbrot; Robert A Lazarus
Journal:  Nat Chem Biol       Date:  2014-05-25       Impact factor: 15.040

3.  An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Authors:  Cassie J Liu; Douglas S Jones; Ping-Chuan Tsai; Abhishek Venkataramana; Jennifer R Cochran
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

Review 4.  Allostery in trypsin-like proteases suggests new therapeutic strategies.

Authors:  David W Gohara; Enrico Di Cera
Journal:  Trends Biotechnol       Date:  2011-07-02       Impact factor: 19.536

5.  Allosteric targeting of receptor tyrosine kinases.

Authors:  Frederik De Smet; Arthur Christopoulos; Peter Carmeliet
Journal:  Nat Biotechnol       Date:  2014-11       Impact factor: 54.908

6.  Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.

Authors:  Peng Xu; Mingming Xu; Longguang Jiang; Qinglan Yang; Zhipu Luo; Zbigniew Dauter; Mingdong Huang; Peter A Andreasen
Journal:  J Med Chem       Date:  2015-11-12       Impact factor: 7.446

7.  A novel synthetic small molecule YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway.

Authors:  Fujun Dai; Yihua Chen; Li Huang; Jinhua Wang; Tao Zhang; Jingjie Li; Weiguang Tong; Mingyao Liu; Zhengfang Yi
Journal:  J Cell Mol Med       Date:  2014-10-29       Impact factor: 5.310

8.  Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies.

Authors:  Masataka Umitsu; Katsuya Sakai; Satoshi Ogasawara; Mika K Kaneko; Ryoko Asaki; Keiko Tamura-Kawakami; Yukinari Kato; Kunio Matsumoto; Junichi Takagi
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

9.  Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.

Authors:  Claudia Desole; Simona Gallo; Annapia Vitacolonna; Elisa Vigna; Cristina Basilico; Francesca Montarolo; Francesca Zuppini; Elena Casanova; Riccardo Miggiano; Davide Maria Ferraris; Antonio Bertolotto; Paolo Maria Comoglio; Tiziana Crepaldi
Journal:  Front Immunol       Date:  2021-12-03       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.